Chemotherapy Induced Neutropenia (CIN) Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Chemotherapy Induced Neutropenia (CIN) Market is segmented By Treatment (Granulocyte Colony-Stimulating Factors (G-CSFs) (Filgrastim, Pegfilgrastim, Lenograstim, Lipegfilgrastim), Antibiotics, Antifungals), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Cancer Type (Breast Cancer, Lung Cancer, Ovarian Cancer, Acute Myeloid Leukemia (AML), Lymphoma), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned.

Chemotherapy Induced Neutropenia (CIN) Market is segmented By Treatment (Granulocyte Colony-Stimulating Factors (G-CSFs) (Filgrastim, Pegfilgrastim, L....

Chemotherapy Induced Neutropenia (CIN) Market Size

Market Size in USD

CAGR4.9%

Study Period	2024 - 2031
Base Year of Estimation	2023
CAGR	4.9%
Market Concentration	Medium
Major Players	Amgen Inc., Sandoz, Teva Pharmaceutical Industries Ltd., Coherus BioSciences, Mylan N.V.

*Disclaimer: Major players are listed in no particular order.

*Source: Coherent Market Insights

Want to purchase customized report?
please let us know !

Chemotherapy Induced Neutropenia (CIN) Market Analysis

The chemotherapy induced neutropenia (CIN) market is estimated to be valued at USD 14.16 Bn in 2024 and is expected to reach USD 19.78 Bn by 2031, growing at a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031. The growth of this market is primarily driven by the growing prevalence of cancer cases worldwide and increasing adoption of chemotherapy as an effective treatment modality.

Chemotherapy Induced Neutropenia (CIN) Market Report Snapshots

Buy Now